Teva Announces Long-Term Data Of Austedo In Adult Patients With Tardive Dyskinesia

Teva Pharmaceuticals announced results from a post hoc analysis of a long-term, 3-year open-label extension (OLE) study examining efficacy and safety endpoints for the use of Austedo (deutetrabenazine) tablets in younger (<55 years) and older (=55 years) patients with tardive dyskinesia.

The company said that safety profile of Austedo was generally similar across both the younger and older patients. No determination of statistical significance can be made, due to the uncontrolled nature of the data and post hoc analysis.

The findings, published online in The American Journal of Geriatric Psychiatry, evaluated the long-term use of Austedo with the total motor Abnormal Involuntary Movements Scale (AIMS) score, and measures of treatment success and quality of life.

Austedo tablets is indicated in adults for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia in adults.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Philips Electronics NV were losing around 2 percent in the morning trading in Amsterdam after the Dutch consumer electronics giant on Monday trimmed its outlook for fiscal 2021 after reporting weak EBITA and sales in its third quarter. The results were hurt by supply chain challenges as well as Sleep & Respiratory Care recall. However, quarterly net profit was significantly higher. The Goldman Sachs Group, Inc. (GS) reported that its third quarter net earnings applicable to common shareholders increased 63 percent year-on-year. Net revenues were also significantly higher reflecting significantly higher net revenues in Investment Banking, Global Markets and Consumer & Wealth Management,... Butterball, LLC recalled about 14,107 pounds of ground turkey products for potential contamination with foreign materials, specifically blue plastic material, the U.S. Department of Agriculture's Food Safety and Inspection Service (FSIS) said in a statement.
Follow RTT